Ipamorelin: A Selective Switch on the Same GH Pulse

The short version

Ipamorelin is a small, lab-made peptide — just five amino acids — that triggers growth hormone (GH) release through a completely different switch than sermorelin or tesamorelin use. Instead of the GHRH receptor, it activates the ghrelin receptor (also called GHS-R1a), the same receptor the 'hunger hormone' ghrelin normally binds. Activating that receptor on the pituitary triggers a pulse of GH release.

What makes ipamorelin stand out among older GH-releasing peptides is what it doesn't do: at doses far above what's needed to release GH, it doesn't meaningfully raise cortisol, ACTH, or prolactin the way earlier compounds like GHRP-6 did — a selectivity that's its defining pharmacological feature. Because it works through a different mechanism than a GHRH analog, it's frequently studied and used alongside one rather than instead of one.

Ipamorelin has never been approved as a drug anywhere, and its only published human efficacy trial missed its primary endpoint. This page reports the published research; it names no dose for any person to take.

What it is

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — alpha-aminoisobutyric acid at the first position, with D-2-naphthylalanine and D-phenylalanine at two other positions conferring resistance to enzymatic breakdown. It's also referenced in the literature by the code NNC 26-0161. Structurally, it was derived from an earlier peptide, GHRP-1, by removing a central two-amino-acid segment. Pharmacologically, it's classified as a selective agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a) — a research peptide, not an approved drug.

How it works

Ipamorelin selectively activates the ghrelin / growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotroph cells, triggering a pulse of growth hormone release. Unlike earlier growth-hormone-releasing peptides such as GHRP-6 and GHRP-2, it does this without meaningfully raising ACTH, cortisol, or prolactin — even at doses far above the amount needed to trigger its GH effect — which is the signature feature that distinguishes it in the pharmacology literature. Because it works through the ghrelin receptor rather than the GHRH receptor that sermorelin and tesamorelin use, its mechanism is distinct from and complementary to theirs, which is the pharmacological basis for combining a ghrelin-receptor agonist like ipamorelin with a GHRH analog such as CJC-1295 in research protocols.

What the research shows

Ipamorelin's human trial record is thin, and the honest starting point is its one and only published Phase 2 randomized controlled trial: 114 adults undergoing bowel resection received ipamorelin 0.03 mg/kg IV twice daily for up to 7 days to test whether it would speed recovery of bowel function after surgery. It missed its primary endpoint — median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo (P=0.15), a difference that didn't reach statistical significance. Treatment-emergent adverse events were actually slightly less common in the ipamorelin arm (87.5%) than placebo (94.8%), which is reassuring on safety in this short perioperative window, but the trial did not demonstrate the efficacy it was designed to test ^[15].

The clearest human pharmacokinetic picture comes from an earlier dosing study in eight healthy male volunteers per dose level, given single 15-minute IV infusions across a wide dose range. It found dose-proportional, linear kinetics: a terminal half-life of roughly 2 hours, and a single discrete GH pulse peaking about 40 minutes after dosing ^[16].

The most recent published animal data (2024) come from a ferret model of cisplatin-induced weight loss and nausea, where ipamorelin reduced chemotherapy-associated weight loss by roughly 24% during the delayed phase (48-72 hours) — but showed no anti-emetic effect on either the acute or delayed nausea, in contrast to a related compound tested in the same study that did reduce acute nausea via a central mechanism ^[13].

Preclinical rat data going back to 1999 found subcutaneous ipamorelin dose-dependently increased longitudinal bone growth rate — from 42 to as much as 52 micrometers/day at the highest dose — without any measurable change in total IGF-1 or bone turnover markers, suggesting a partly local, GH-pulse-driven skeletal effect rather than one mediated purely through systemic IGF-1 ^[17].

On the safety side, it's worth being precise about what's actually been studied and what hasn't: a 28-day chronic dosing study found dose-dependent myocardial degeneration and necrosis in rats given a different, structurally distinct ghrelin-receptor agonist — not ipamorelin itself — detectable by histopathology and electron microscopy. Ipamorelin was not the compound tested, but the finding is a class-level cardiovascular-toxicity signal from a chronic dosing study, and no equivalent long-duration safety study of ipamorelin itself exists in any species ^[14].

Reported effects, cautions & safety

What follows is anecdotal, not clinical evidence — reports gathered from peptide-user forums, telehealth-adjacent blogs, and wellness-clinic write-ups about ipamorelin, most often used alongside a GHRH analog like CJC-1295 rather than alone. None of it comes from controlled trials, doses aren't verified, and none of it should be read as a recommendation.

Reported benefits: deeper, more restorative sleep is the most consistently cited benefit — users describe falling asleep faster, sleeping more deeply, and waking more rested, often within the first one to two weeks of a pre-bed protocol. Vivid or intense dreams are frequently mentioned in that same early window, often read as a sign of enhanced REM activity before settling into more stable deep sleep. Faster physical recovery and reduced post-training soreness are commonly reported, along with occasional mentions of better joint feel over weeks of use. A gradual shift toward a leaner body composition over five to twelve weeks is occasionally reported too, though users themselves note it's confounded by concurrent diet and training changes.

Reported adverse effects: a warm facial flush or head-rush in the 5-15 minutes after injection — often compared to a niacin flush — is widely and frequently reported, and is commonly (though not confirmedly) read by users as a sign the peptide is active. Tingling or mild numbness in the hands and feet, transient water retention or puffiness, and a noticeable uptick in appetite after injection are all occasionally reported, the last one tracking with ipamorelin's action on the ghrelin receptor, which also governs hunger signaling. Mild injection-site redness, itching, or swelling and, occasionally, transient dizziness or a 'spacey' feeling shortly after dosing are also described. A recurring theme worth naming honestly: some users report the perceived effects — especially sleep improvements — seem to fade after three to four months of continuous use, which is the community's stated reason for cycling on and off rather than dosing continuously.

Cited safety cautions:

• Active or recent malignancy, or other proliferative conditions, is a mechanistic concern: GH-axis stimulation raises IGF-1, a well-characterized mitogen. No ipamorelin-specific human carcinogenicity data exist; the caution is class-level and mechanistic, not drawn from observed events in any ipamorelin trial ^[17].
• Diabetes, impaired glucose tolerance, or insulin resistance deserve caution for two separate reasons: GH itself reduces peripheral insulin sensitivity at sustained levels, and ipamorelin has also shown a direct, GH-independent insulin-releasing effect on pancreatic tissue in laboratory studies — a dual mechanism that makes the net glycemic effect in someone with pre-existing insulin dysregulation genuinely unpredictable, especially since no human glycemic data at research-use doses exist for ipamorelin.
• Active cardiovascular disease, heart failure, or significant edema warrant caution: GH excess is associated with fluid retention and cardiac changes in general, and — as noted above — a chronic 28-day dosing study of a related ghrelin-receptor agonist (not ipamorelin) found dose-dependent heart-muscle toxicity in rats. No equivalent long-duration cardiovascular study of ipamorelin exists in any species ^[14].
• Appetite dysregulation and adiposity-related conditions are a relevant caution given the mechanism: ghrelin-receptor agonists activate hypothalamic appetite centers directly, and ipamorelin specifically has shown GH-independent effects on adiposity and leptin in animal studies — meaning some of the body-composition effect doesn't run through the GH axis at all.
• Long-term human safety is genuinely unknown, and research-grade material's purity is unverified: the entire controlled human ipamorelin dataset consists of one short perioperative RCT and one small acute-dosing pharmacokinetic study — no Phase 3 trial, and no long-term safety database, exists ^[15][16].
• One comparative note in ipamorelin's favor: unlike older GH-releasing peptides such as GHRP-6 and GHRP-2, it doesn't meaningfully raise cortisol or prolactin even at doses far above what's needed for its GH effect — a real, mechanistically grounded selectivity advantage, not a claim that it has no other off-target effects.

Where it fits in the Growth Hormone Axis

Ipamorelin is the odd one out mechanically, and that's exactly why it belongs on this list: where sermorelin and tesamorelin both work through the GHRH receptor — one as a natural fragment, one as an engineered analogue — ipamorelin pulls the same GH-release lever through an entirely separate receptor, the ghrelin receptor. That's the mechanistic reason it shows up so often paired with a GHRH analog in research protocols rather than used on its own. Of the three compounds here, it also has the thinnest confirmed human evidence base — one Phase 2 trial that missed its primary endpoint — which is worth weighing against the enthusiasm in community reporting. See the comparison page to weigh evidence maturity across all three.